2.86
0.01 (0.35%)
| Penutupan Terdahulu | 2.85 |
| Buka | 2.87 |
| Jumlah Dagangan | 88,824 |
| Purata Dagangan (3B) | 564,281 |
| Modal Pasaran | 510,911,296 |
| Harga / Buku (P/B) | 31.75 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 21 Jul 2025 - 25 Jul 2025 |
| Margin Keuntungan | -145.66% |
| Margin Operasi (TTM) | 3.58% |
| EPS Cair (TTM) | -0.050 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 31.30% |
| Nisbah Semasa (MRQ) | 20.59 |
| Aliran Tunai Operasi (OCF TTM) | -9.55 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 1.63 M |
| Pulangan Atas Aset (ROA TTM) | -24.05% |
| Pulangan Atas Ekuiti (ROE TTM) | -37.20% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (AU) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | RACEONCO FPO [RAC] | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.00 |
|
Race Oncology Ltd is a clinical stage biopharmaceutical company with a mission to be at the heart of cancer care. Its asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult and pediatric patients, a well-characterized safety profile, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. It has reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where Race can deliver cardioprotection and enhanced anticancer activity in solid tumors. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 31.24% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |